ANTX
What one share of AN2 Therapeutics holds
Pharmaceutical Preparations
We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to initiate in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases.
AN2 Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.04 |
|---|---|
| Cash and investments | $1.22 |
| Book value | $2.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$10.64 | — | −$7.76 | — | −$17.36 |
| 2022 | — | −$2.79 | — | −$2.18 | — | $4.92 |
| 2023 | — | −$2.74 | — | −$2.26 | — | $4.19 |
| 2024 | — | −$1.72 | — | −$1.65 | — | $2.74 |
| 2025 | — | −$1.16 | — | −$0.99 | — | $1.94 |